243 related articles for article (PubMed ID: 18391982)
1. Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3beta with p53.
Matsui Y; Watanabe J; Ikegawa M; Kamoto T; Ogawa O; Nishiyama H
Oncogene; 2008 Jul; 27(33):4603-14. PubMed ID: 18391982
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells.
Kiviharju TM; Lecane PS; Sellers RG; Peehl DM
Clin Cancer Res; 2002 Aug; 8(8):2666-74. PubMed ID: 12171899
[TBL] [Abstract][Full Text] [Related]
3. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
Carter BZ; Mak DH; Schober WD; Dietrich MF; Pinilla C; Vassilev LT; Reed JC; Andreeff M
Blood; 2008 Apr; 111(7):3742-50. PubMed ID: 18187663
[TBL] [Abstract][Full Text] [Related]
4. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells.
Jiang XH; Wong BC; Lin MC; Zhu GH; Kung HF; Jiang SH; Yang D; Lam SK
Oncogene; 2001 Nov; 20(55):8009-18. PubMed ID: 11753684
[TBL] [Abstract][Full Text] [Related]
5. MAPKs are not involved in triptolide-induced cell growth inhibition and apoptosis in prostate cancer cell lines with different p53 status.
Li W; Liu Y; Li XX; Yu Y; Wu JJ; Wang Q; Huo H; Wang LM; Yang L
Planta Med; 2011 Jan; 77(1):27-31. PubMed ID: 20607649
[TBL] [Abstract][Full Text] [Related]
6. Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas.
Wu J; Li QQ; Zhou H; Lu Y; Li JM; Ma Y; Wang L; Fu T; Gong X; Weintraub M; Wu S; Ding H
Med Oncol; 2014 Jul; 31(7):14. PubMed ID: 24880464
[TBL] [Abstract][Full Text] [Related]
7. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species.
Matsui Y; Ueda S; Watanabe J; Kuwabara I; Ogawa O; Nishiyama H
Cancer Res; 2007 Feb; 67(3):1212-20. PubMed ID: 17283157
[TBL] [Abstract][Full Text] [Related]
8. Triptolide induces Bcl-2 cleavage and mitochondria dependent apoptosis in p53-deficient HL-60 cells.
Wan CK; Wang C; Cheung HY; Yang M; Fong WF
Cancer Lett; 2006 Sep; 241(1):31-41. PubMed ID: 16316721
[TBL] [Abstract][Full Text] [Related]
9. Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines.
Watanabe J; Nishiyama H; Matsui Y; Ito M; Kawanishi H; Kamoto T; Ogawa O
Oncogene; 2006 Apr; 25(17):2500-8. PubMed ID: 16518417
[TBL] [Abstract][Full Text] [Related]
10. Triptolide induces apoptosis in endometrial cancer via a p53‑independent mitochondrial pathway.
Wang XF; Zhao YB; Wu Q; Sun ZH; Li HJ
Mol Med Rep; 2014 Jan; 9(1):39-44. PubMed ID: 24213358
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor effect of triptolide and cisplatin in cisplatin resistant human bladder cancer cells.
Ho JN; Byun SS; Lee S; Oh JJ; Hong SK; Lee SE; Yeon JS
J Urol; 2015 Mar; 193(3):1016-22. PubMed ID: 25229559
[TBL] [Abstract][Full Text] [Related]
12. Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer.
Xiong J; Su T; Qu Z; Yang Q; Wang Y; Li J; Zhou S
Oncotarget; 2016 Apr; 7(17):23933-46. PubMed ID: 27004407
[TBL] [Abstract][Full Text] [Related]
13. Effects of triptolide from Tripterygium wilfordii on ERalpha and p53 expression in two human breast cancer cell lines.
Liu J; Jiang Z; Xiao J; Zhang Y; Lin S; Duan W; Yao J; Liu C; Huang X; Wang T; Liang Z; Wang R; Zhang S; Zhang L
Phytomedicine; 2009 Nov; 16(11):1006-13. PubMed ID: 19524422
[TBL] [Abstract][Full Text] [Related]
14. Triptolide suppresses interleukin-1beta-induced human beta-defensin-2 mRNA expression through inhibition of transcriptional activation of NF-kappaB in A549 cells.
Jang BC; Lim KJ; Choi IH; Suh MH; Park JG; Mun KC; Bae JH; Shin DH; Suh SI
Int J Mol Med; 2007 May; 19(5):757-63. PubMed ID: 17390080
[TBL] [Abstract][Full Text] [Related]
15. Synergism of cytotoxicity effects of triptolide and artesunate combination treatment in pancreatic cancer cell lines.
Liu Y; Cui YF
Asian Pac J Cancer Prev; 2013; 14(9):5243-8. PubMed ID: 24175808
[TBL] [Abstract][Full Text] [Related]
16. Triptolide sensitizes liver cancer cell lines to chemotherapy in vitro and in vivo.
Li Y; Hu S
Panminerva Med; 2014 Sep; 56(3):211-20. PubMed ID: 24352031
[TBL] [Abstract][Full Text] [Related]
17. Triptolide inhibits viability and induces apoptosis in liver cancer cells through activation of the tumor suppressor gene p53.
Sun YY; Xiao L; Wang D; Ji YC; Yang YP; Ma R; Chen XH
Int J Oncol; 2017 Mar; 50(3):847-852. PubMed ID: 28098861
[TBL] [Abstract][Full Text] [Related]
18. Triptolide induces mitochondria-mediated apoptosis of Burkitt's lymphoma cell via deacetylation of GSK-3β by increased SIRT3 expression.
Kong J; Wang L; Ren L; Yan Y; Cheng Y; Huang Z; Shen F
Toxicol Appl Pharmacol; 2018 Mar; 342():1-13. PubMed ID: 29407771
[TBL] [Abstract][Full Text] [Related]
19. Dicoumarol enhances doxorubicin-induced cytotoxicity in p53 wild-type urothelial cancer cells through p38 activation.
Matsui Y; Watanabe J; Ding S; Nishizawa K; Kajita Y; Ichioka K; Saito R; Kobayashi T; Ogawa O; Nishiyama H
BJU Int; 2010 Feb; 105(4):558-64. PubMed ID: 19583730
[TBL] [Abstract][Full Text] [Related]
20. Triptolide circumvents drug-resistant effect and enhances 5-fluorouracil antitumor effect on KB cells.
Chen YW; Lin GJ; Chuang YP; Chia WT; Hueng DY; Lin CK; Nieh S; Sytwu HK
Anticancer Drugs; 2010 Jun; 21(5):502-13. PubMed ID: 20154595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
